35
Participants
Start Date
February 9, 2022
Primary Completion Date
May 3, 2023
Study Completion Date
April 19, 2024
Sodium Chloride
Administered intranasal (IN) and intramuscular (IM) in combination
NDV-HXP-S IN low dose
"Allantoic fluid diluted in Phosphate buffered saline (PBS), to be further diluted to dose strength in sodium chloride.~Strength: 3.3x108\^8 EID50."
NDV-HXP-S IM low dose
"Allantoic fluid diluted in Phosphate buffered saline (PBS), to be further diluted to dose strength in sodium chloride.~Strength: 3.3x10\^8 EID50."
NDV-HXP-S IN high dose
Allantoic fluid diluted in Phosphate buffered saline (PBS). Strength: 1x10\^9 EID50.
NDV-HXP-S IM high dose
Allantoic fluid diluted in Phosphate buffered saline (PBS). Strength: 1x10\^9 EID50.
Icahn School of Medicine at Mount Sinai, New York
Sean Liu
OTHER